©2024 Cognivue, Inc. | Privacy Policy | References
TECHNOLOGY
Leading the way in early detection of cognitive impairment
The First FDA cleared digital cognitive screening device
Cognivue’s® proprietary FDA-cleared technology is based on adaptive psychophysics. The technology collects 130,000 data points creating a unique patient experience customized to their individual visual and motor skills. This reliable test is validated against other recognized gold-standard cognitive assessment tools, while providing an experience custom to each patient. It is a self-administered computerized assessment which removes the bias that can be associated with more traditional cognitive assessment tools, standardizing your approach to testing.
Self-Administered
Dynamic Testing
Comprehensive Results
Cognitive Assessment Devices
Cognivue offers two devices. First, an abbreviated cognitive screening device, the Cognivue Thrive® test detects potential cognitive impairment so that a patient can address modifiable risk factors to potentially change the course of the impairment. Second, a more comprehensive assessment device, the Cognivue Clarity® test provides more in-depth data points to supplement a full neurological assessment assisting the doctor in arriving at a differential diagnosis.
Recommendations available to educate patients on evidence-based ways to manage lifestyle-related risk factors.
Cognivue Thrive® and Clarity® are indicated for use as adjunctive tools for evaluating cognitive function. They are not a stand-alone diagnostic tool and do not identify the presence or absence of clinical diagnoses. The device results are to be assessed and interpreted by a licensed clinician. Cognivue, Cognivue Thrive, Cognivue Clarity and Cogniwell are trademarks or registered trademarks of Cognivue, in the US and/or other countries. 2023 Cognivue. All rights reserved.